FISCHER JOST 4

What Happened Jost Fischer, a director of AEON Biopharma (AEON), was granted 222,684 restricted stock units (RSUs) on June 17, 2026. The award shows an acquisition price of $0.00 (i.e., a compensation grant rather than a cash purchase). The RSUs will convert to shares if and when they vest; there was no immediate sale or cash proceeds reported.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (appears to be one business day late vs. the 2-business-day Form 4 deadline).
• Transaction type/code: Award/Grant (Code A).
• Shares granted: 222,684 RSUs; reported acquisition price: $0.00; total cash paid: $0.
• Vesting: RSUs vest in full on the earlier of (i) the one-year anniversary of the grant (June 17, 2027) or (ii) the date of the 2027 annual meeting of stockholders, subject to continued service (per footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.

Context RSUs are a form of equity compensation that become actual shares only upon vesting; they do not represent an immediate purchase and typically reflect retention/compensation rather than a straightforward bullish buy signal. Because this was a grant, there were no proceeds or immediate market-impacting trades reported. The slightly late filing may be noted by investors but does not itself indicate insider intent.